跳至主要内容
临床试验/NCT00665574
NCT00665574终止不适用

A Prospective, Multi-center, Randomized, Double-blind Feasibility Study to Evaluate the Safety and Performance of ActaVisc and ActaVisc Mx Intra-articular Injection for Management of Pain Associated With Osteoarthritis in the Knee.

Carbylan Therapeutics, Inc.2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
23
试验地点
2
主要终点
Change from Baseline in the WOMAC Pain subscale average score for the treatment knee.

研究概览

简要总结

To evaluate the safety and performance of ActaVisc™ intra-articular injection (ActaVisc) and ActaVisc Mx, for management of pain associated with osteoarthritis in the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
40 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Osteoarthritis (OA) grade 2 or
  • Symptoms in the treatment knee for at least 12 months.
  • Fully ambulatory patient.

排除标准

  • Secondary OA resulting from rheumatoid arthritis, chondrocalcinosis, osteonecrosis, chronic fibromyalgia or other autoimmune disease.
  • Generalized symptomatic OA in lower extremity joints other than the knees, inflammatory joint disease, bursitis, OA in the hips, or other condition that may interfere with study assessments.

结局指标

主要结局

Change from Baseline in the WOMAC Pain subscale average score for the treatment knee.

时间窗: 26 weeks post treatment

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验